Drugs that contain Aliskiren Hemifumarate; Amlodipine Besylate
1. Tekamlo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Aug 26, 2013 |
NCE-1 date: 06 March, 2011
Market Authorisation Date: 26 August, 2010
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
TEKAMLO family patents
